Request Sample Inquiry
Antibody Drug Conjugates (adcs) Market

Antibody Drug Conjugates (ADCS) Market

Antibody Drug Conjugates (ADCS) Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

155

Base Year:

2022

Date

Feb - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1280

Segments Covered
  • By Application By Application Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer
  • By Technology By Technology Cleavable Linker, Non-Cleavable Linker, Linkerless
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 4.75 Billion
Revenue 2030Revenue 2030: USD 18.84 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 18.80%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst

Research Methodology: Antibody Drug Conjugates (ADCS) Market by Application by Technology by Region - Global Market Assessment, 2021 - 2028

Secondary Research

Primary Research:

The later stage covers data validation and collection from primary research. The information gained/procured from the secondary data sources is validated through extensive primary interviews with industry experts across the Antibody Drug Conjugates (ADCS) supply chain. The primary research is also conducted to identify key players in the market and to gather and validate already procured information pertaining to their market-specific financial information. Moreover, primary research is used to gain/validate information about:


  • Antibody Drug Conjugates (ADCS) market size at regional and country level
  • Key industry players and their market share and Antibody Drug Conjugates (ADCS) market-specific sales/revenue
  • Understanding of the Antibody Drug Conjugates (ADCS) supply chain and overall ecosystem

Data Triangulation and Market Size Estimations

After arriving at the global market numbers, top-down and bottom-up approaches are used to estimate, validate and finalize the market size of the Antibody Drug Conjugates (ADCS) market. After the determination of the overall market size, the market is divided into various segments and sub-segments. Moreover, these same approaches mentioned above were used to derive and estimate market numbers for mentioned segments/sub-segments in the market. During the data triangulation process, the data was analyzed by employing various data models and statistical techniques to arrive at exact statistics and market size for each segment/sub-segment of the market.  The data is analyzed and triangulated by considering all the key market impacting factors from both supply and demand side of Antibody Drug Conjugates (ADCS) market. 

FAQ
Frequently Asked Question
  • The global Antibody Drug Conjugates (ADCS) valued at USD 4.75 Billion in 2022 and is expected to reach USD 18.84 Billion in 2030 growing at a CAGR of 18.80%.

  • The prominent players in the market are Takeda Pharmaceutical Company Ltd. (Japan), F. Hoffmann-La Roche Ltd. (US), Pfizer Inc. (US), AstraZeneca (Sweden), Gilead Sciences Inc. (US), Astellas Pharma (Japan), Seagen Inc. (US), Daiichi Sankyo Company Ltd. (Japan), GlaxoSmithKline PLC (UK), ADC Therapeutics (Switzerland).

  • The market is project to grow at a CAGR of 18.80% between 2023 and 2030.

  • The driving factors of the Antibody Drug Conjugates (ADCS) include

    • Significant Investment in Research and Development

  • North America was the leading regional segment of the Antibody Drug Conjugates (ADCS) in 2022.